Figure 2 | Scientific Reports

Figure 2

From: A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics

Figure 2

Cell-based ASST activity in UPEC CFT073 in varying concentrations of DsbA inhibitor F1. Sulfotransferase activity of (A) CFT073/pASST, CFT073/pSU2718 (vector control), CFT073ΔdsbA/pASST, and CFT073ΔdsbAΔdsbLI/pASST cultured in 0.4% DMSO in the absence of DsbA inhibitors. (B) Sulfotransferase activity of CFT073/pASST cultured in the presence of F1 (1–0.125 mM) or 0.4% DMSO (vehicle control) and (C) corresponding F1 dose–response curve calculated at 40-min time point. F1 treated bacterial cultures were mixed with MUS and phenol and immediately monitored spectrofluorometrically (excitation 360 nm and emission 450 nm) for 60 min at room temperature (21 °C). Data are shown as normalised fluorescence intensity units (calculated by normalising the treatment data against the DMSO control (set as 100%) (A and B: slopes reported in (B) were calculated from the 15 to 30 min region), and normalised fluorescence intensity at 40 min (C) (calculated from the 40-min time point of B), with the mean ± SD of 3 biological replicates plotted at each time point.

Back to article page